Precivity AD2 Blood Test:
In late 2022, C2N announced that it had developed the PrecivityAD2™ blood test, which measures the p-Tau217 ratio and the AB42/40 ratio in plasma and uses a statistical algorithm to integrate a patient’s Aβ42/40 Ratio and p-Tau217 Ratio to calculate the Amyloid Probability Score 2 (APS2). The APS2 determines whether a patient is positive or negative for brain amyloid plaques based on a binary cutoff value. The launch of the Precivity AD2 blood test is expected sometime in early 2023.
